504906013 05/09/2018

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4952757

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
PHILIP G. STIMPSON	05/07/2018

RECEIVING PARTY DATA

Name:	LABORIE MEDICAL TECHNOLOGIES CANADA ULC	
Street Address:	6415 NW DRIVE, UNIT 11	
City:	MISSISSAUGA, ONTARIO	
State/Country:	CANADA	
Postal Code:	L4V1X1	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	14774603

CORRESPONDENCE DATA

Fax Number: (954)728-1282

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 954-939-3368

Email: IPdocketing@lewisbrisbois.com

Correspondent Name: HOWARD GITTEN-LEWIS BRISBOIS
Address Line 1: 110 SE 6TH STREET, SUITE 2600
Address Line 4: FORT LAUDERDALE, FLORIDA 33301

ATTORNEY DOCKET NUMBER:	14778-4010US
NAME OF SUBMITTER:	HOWARD G. GITTEN
SIGNATURE:	/howard g gitten/
DATE SIGNED:	05/09/2018

Total Attachments: 2

source=Assignment Executed#page1.tif source=Assignment Executed#page2.tif

PATENT 504906013 REEL: 045750 FRAME: 0303

ASSIGNMENT & APPOINTMENT OF COMMON REPRESENTATIVE

WHEREAS, I, Philip G. Stimpson of West Palm Beach, FL has invented a certain new and useful invention(s) disclosed in a United States patent application entitled CATHETER ASSEMBLY for which a patent application has been prepared and filed with the U.S. Patent & Trademark Office on September 10, 2015 receiving Serial No. 14/774,603 and further identified as Attorney Docket No.: 14778 - 4010US.

NOW THEREFORE, be it known that we, for and in consideration of certain good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, at the request of the assignee do sell, assign and transfer unto said assignee, LABORIE MEDICAL TECHNOLOGIES CANADA ULC, a Florida corporation having a place of business at 6415 NW Drive, Unit 11, Mississauga, Ontario, Canada LAV1X1, its successors, legal representatives and assigns, the aforesaid application and all rights to claim priority directly or indirectly to the aforesaid application and all continuation, divisional, continuation-in-part and reissue applications, all patent applications that claim priority directly or indirectly to the aforesaid application, all patent applications in foreign countries, all applications pursuant to the Patent Cooperation Treaty and all applications for extension filed or to be filed for the invention(s), and all Letters Patent, Invention Registrations, Utility Models, Extensions or Reissues and other patent rights, obtained for the invention(s) in the United States or any other country; we also assign any right, title or interest in and to the invention(s) that has not already been transferred to the assignee; we warrant that no assignment of the invention(s), application or patent therefor has been made to a party other than LABORIE MEDICAL TECHNOLOGIES CANADA ULC; we warrant that there is no obligation to make any assignment of the invention(s), application, or any patent therefor to any party other than LABORIE MEDICAL TECHNOLOGIES CANADA ULC: and we further agree to cooperate with the assignee hereunder in the obtaining and sustaining of any and all such Letters Patent and in confirming assignee's exclusive ownership of the invention(s), but at the expense of said assignee.

The Commissioner For Patents is hereby authorized and requested to issue the Letters Patent solely in accordance with the terms of this Assignment to LABORIE MEDICAL

Application Serial No.: 14/774,603 Attorney Docket No.: 14778 – 4010US

TECHNOLOGIES CANADA ULC, its successors, legal representatives and assigns, as the assignee of the entire right, title and interest therein.

Furthermore, we hereby irrevocably appoint LABORIE MEDICAL TECHNOLOGIES CANADA ULC, its successors, legal representatives and assigns, as common representative for any and all international patent applications filed pursuant to the Patent Cooperation Treaty, and all national phase applications derived therefrom, concerning the invention(s) or claiming priority from the aforesaid application.

IN WITNESS WHEREOF, the party hereto has executed this Assignment & Appointment of Common Representative as of the date indicated hereunder.

Date: 7 HAT 7018

Philip G. Stimoso

Page 2 of 2